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A role for antibiotic biosynthesis monooxygenase
domain proteins in fidelity control during aromatic
polyketide biosynthesis
Zhiwei Qin 1,3, Rebecca Devine 2,3, Matthew I. Hutchings 2 & Barrie Wilkinson 1
The formicamycin biosynthetic gene cluster encodes two groups of type 2 polyketide anti-
biotics: the formicamycins and their biosynthetic precursors the fasamycins, both of which
have activity against methicillin-resistant Staphylococcus aureus. Here, we report the for-
micapyridines which are encoded by the same gene cluster and are structurally and bio-
synthetically related to the fasamycins and formicamycins but comprise a rare pyridine
moiety. These compounds are trace-level metabolites formed by derailment of the major
biosynthetic pathway. Inspired by evolutionary logic we show that rational mutation of a
single gene in the biosynthetic gene cluster encoding an antibiotic biosynthesis mono-
oxygenase (ABM) superfamily protein leads to a significant increase both in total for-
micapyridine production and their enrichment relative to the fasamycins/formicamycins. Our
observations broaden the polyketide biosynthetic landscape and identify a non-catalytic role
for ABM superfamily proteins in type II polyketide synthase assemblages for maintaining
biosynthetic pathway fidelity.
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An idealised linear biosynthetic pathway to a complexnatural product can be imagined proceeding through aseries of intermediate structures which would exist for
some finite time as the pathway product accumulates. These
hypothetical intermediates would exist freely in solution or bound
to enzymes in the case of assembly line processes, and eventually
all flux through the pathway would end and only the final product
would exist. In reality no pathways proceed in this manner as the
situation is complicated by varying rates of reaction for the dif-
ferent steps, meaning that some intermediates accumulate, while
the inherent reactivity of other intermediates, or their ability to
act as substrates for housekeeping enzymes not dedicated to the
pathway, means that shunt metabolites often arise. Matters are
further complicated by the fact that pathways are often con-
vergent, with multiple units made in parallel before assembly into
the final product, for example in the biosynthetic pathways to
macrolide or aminoglycoside1 antibiotics. In addition, some
pathways are not linear, and the final product is accessed via
several routes due to the inherent substrate plasticity of the bio-
synthetic enzymes; well-studied examples include the rapamycin
and erythromycin pathways2. Thus, in practice, any biosynthetic
pathway will lead to the accumulation of a mixture comprising
the final product plus varying concentrations of pathway inter-
mediates and shunt metabolites. The composition of such a
mixture will vary further when alternate growth conditions are
used3. Sometimes the final product of the pathway cannot be
clearly discerned.
Such mixtures of compounds are said to comprise a series of
biosynthetic congeners, and their identification can provide
valuable information about a biosynthetic pathway and may
sometimes lead to new biosynthetic understanding4. We
recently reported the formicamycins, aromatic polyketides
produced by Streptomyces formicae KY5 isolated from the
fungus-growing plant-ant Tetroponera penzigi (Fig. 1)5. In
total, sixteen congeners were isolated including three more
fasamycins, a group of compounds previously reported from
the heterologous expression of a clone derived from environ-
mental DNA6. These congeners are the product of a type II
polyketide synthase (PKS) operating in conjunction with post-
PKS modifications that include O-methylation and halogena-
tion, plus oxidative and reductive modifications. Intrigued by
these compounds, which exhibit potent antibacterial activity,
we employed targeted metabolomics to identify further con-
geners that may have been missed during manual analysis
of culture extracts. This led us to identify the formicapyridines
(1–9), pyridine containing polyketide alkaloids which represent
additional products of the formicamycin (for) biosynthetic gene
cluster (BGC). Products of type II PKS systems which contain a
pyridine moiety are rare7.
Challis and co-workers have shown that the majority of acti-
nomycete derived polyketide alkaloids, including those contain-
ing a pyridine moiety, arise from reactive intermediates formed
after transamination of aldehydes generated from reductive off-
loading of the thioester bound polyketide chain from a type I
modular PK8. In contrast, the formicapyridines are minor shunt
metabolites that arise due to derailment of the formicamycin
biosynthetic pathway. We show here that reprogramming the for
BGC, by deleting the forS gene encoding an ABM family protein,
leads to significantly increased production of formicapyridines
with concomitant reduction of the combined titre of fasamycins
and formicamycins. These and other mutational data lead us to
the hypothesis that ForS is not a cyclase but forms part of a
multienzyme complex where it acts as a chaperone-like protein to
aid in maintaining pathway fidelity and performance. The dis-
covery and engineering of formicapyridine biosynthesis raises
intriguing questions regarding the evolution of type II PKS
biosynthetic pathways and the origins of natural product che-
mical diversity.
Results
Metabolomics led identification of the formicapyridines. The
aromatic, polycyclic nature of these molecules limited fragmen-
tation and the effectiveness of molecular networking via the
Global Natural Product Social Molecular Networking web plat-
form9. Instead, as most fasamycin and formicamycin congeners
are halogenated (Fig. 1), we established a bespoke dereplication
method, making use of S. formicae KY5 mutants that we reported
previously, including an entire BGC deletion strain (Δfor), and a
strain in which the halogenase gene was deleted (ΔforV)5 (Fig. 2).
Our earlier study5 showed that the Δfor mutant does not produce
any fasamycins or formicamycins, and the ΔforV mutant pro-
duces only non-halogenated fasamycin congeners.
Replicate (n= 3) ethyl acetate extracts of the wild type (WT),
Δfor and ΔforV strains, along with equivalent extracts from
uninoculated mannitol soya flour (MS) agar plates, were analysed
by liquid chromatography high-resolution mass spectroscopy
(LC-HRMS). Using the Profiling Solutions software (Shimadzu
Corporation), the WT dataset (Supplementary Data 1 and 2) was
filtered to remove ions also present in the other samples. Only
two other BGCs in the S. formicae KY5 genome10 contain
putative halogenase encoding genes, so we hypothesised that any
chlorine-containing ions present in the filtered dataset would
likely derive from the formicamycin BGC. This process
dramatically reduced the dataset complexity, leaving <200 unique
ions from an original set of ∼3000. Manual curation showed that
most of the remaining ions corresponded to halogenated
molecules (based on isotope patterns), leaving twelve previously
identified fasamycin and formicamycin congeners, two additional
fasamycin/formicamycin congeners that remain uncharacterized
due to trace levels, and the known isoflavone 6-chlorogenistein11
(Supplementary Note 1 and Supplementary Figs. 11–14) along
with a regioisomer. Analysis of C/H ratios and m/z data allowed
us to identify a group of three additional metabolites (4–6) with
mass spectra suggesting a close structural relationship to the
fasamycins/formicamycins; these varied only in the number of
methyl groups present. By searching for equivalent ions lacking
chlorine atoms we identified three additional congeners (1–3).
Compounds 1–6 were not initially observed in the UV
chromatograms of the WT, and qualitative examination of
the LCMS data suggested titres at least 100-fold lower than for the
formicamycins. Furthermore, the m/z data implied the presence
of a single nitrogen atom.
We repeated the experiment but included a set of WT strain
fermentations to which sodium bromide (2 mM) was added, as
our previous study showed this leads to the biosynthesis of
brominated formicamycin congeners5. This identified three
conditional bromine-containing metabolites (7–9) with MS
characteristics like those of 4–6 (Fig. 2 and Supplementary Fig. 1),
supporting the hypothesis that these compounds represent
biosynthetic congeners.
Isolation and structure elucidation and biological activity.
HRMS data allowed us to predict molecular formulae for 1–9 that
were used to search the online chemical database REAXYS. This
suggested that they represented new structures. To isolate suffi-
cient material for structure determination and antibacterial
assays, the growth of S. formicae KY5 was scaled up (14 L; ~450
MS agar plates). After 9 days incubation at 30 °C the combined
agar was chopped up, extracted with ethyl acetate, and the solvent
removed under reduced pressure. The resulting extract was sub-
jected to repeated rounds of reversed-phase HPLC followed by
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Sephadex LH-20 size exclusion chromatography leading to small
quantities of purified 1–6.
We first determined the structure of 2 which was isolated in the
largest amount (~2mg). HRMS and 13C NMR data indicated a
molecular formula of C28H25NO6 (calculated m/z 472.1755 ([M+
H]+); observed m/z 472.1753 ([M+H]+); Δ=−0.4 ppm)
indicating 17 degrees of unsaturation. The UV spectrum showed
absorption maxima at 229, 249, 272 and 392 nm indicating a
complex conjugated system different to that of the fasamycins/
formicamycins5. Inspection of the 13C NMR spectrum showed
21 sp2 carbons (δC 99.90–167.54 ppm), one carbonyl carbon (δC
191.81 ppm), four methyl carbons (δC 20.41, 23.59, 34.56 and
37.75 ppm), one methoxy carbon (δC 55.80 ppm) and one sp3
quaternary carbon (δC 40.49 ppm). The 1H NMR spectrum
revealed the presence of five methyl singlets (δH 1.75, 1.76, 1.93,
3.67 and 3.81 ppm), two aromatic proton singlets (δH 7.62 and
7.65 ppm), plus four aromatic proton doublets (δH 6.24 (d, 2.25
Hz), 6.70 (d, 2.25 Hz), 6.34 (d, 2.27 Hz) and 6.42 (d, 2.27 Hz)).
Limited 1H–1H COSY correlations meant we were reliant upon
HMBC-based atomic connections, and through-space NOESY
correlations, which led to two potential substructures consisting of
26 carbon atoms, leaving one carbonyl, one phenol and one
quaternary carbon unassigned (Fig. 3). This left some uncertainty,
but given the relationship with the fasamycins, we predicted the
structure to be that shown for 2. We thus plotted the 13C chemical
shifts for 2 against those for fasamycin C (10), the closest
structural congener. The data were in excellent agreement with the
main differences at C7, C22 and C23, consistent with the adjacent
nitrogen atom (Supplementary Fig. 2). With the structure of 2 in
hand we readily assigned the structures of 1 and 3–6. NOESY
correlations played a key role allowing us to link the methoxy
group at C3 with H2 and H4 (e.g. 2, 3, 5 and 6), and the methoxy
at C5 with H4 (e.g. 3 and 6). We also used NOESY and HSQC
correlations to distinguish C14 and C16 once one was chlorinated:
given the NOESY correlations to the gem-dimethyl groups of C26
and C27 with H16, and the disappearance of a HSQC linkage for
C14, we concluded that C14 was chlorinated (e.g. 4–6).
Compounds 1–6 exhibit optical activity with small [α]20D values
between +8° and +13° indicating probable atropoisomerism
about the axis of the C6–C7 bond. We attempted to assign the
absolute configuration by combining computational approaches
with electronic circular dichroism (ECD) spectra as done for the
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16 Formicamycin C R1 = H, R2 = Cl, R3 = Cl, R4 = H, R5 = CH3
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18 Formicamycin E R1 = Cl, R2 = Cl, R3 = Cl, R4 = H, R5 = CH3 
19 Formicamycin F R1 = Cl, R2 = Cl, R3 = H, R4 = Cl, R5 = CH3 
20 Formicamycin G R1 = H, R2 = Cl, R3 = Cl, R4 = Cl, R5= CH3 
21 Formicamycin H R1 = Cl, R2 = H, R3 = Cl, R4 = Cl, R5 = CH3
22 Formicamycin I R1 = Cl, R2 = Cl, R3 = Cl, R4 = Cl, R5 = H
23 Formicamycin J R1 = Cl, R2 = Cl, R3 = Cl, R4 = Cl, R5 = CH3
24 Formicamycin K R1 = H, R2 = Cl, R3 = Br, R4 = Cl, R5 = CH3
25 Formicamycin L R1 = Cl, R2 = Cl, R3 = Br, R4 = Cl, R5 = CH3
26 Formicamycin M R1 = H, R2 = Br, R3 = H, R4 = H, R5 = CH3
10 Fasamycin C R1 = H, R2 = H, R3 = H, R4 = CH3   
11 Fasamycin D R1 = H, R2 = H, R3 = Cl, R4 = CH3  
12 Fasamycin E R1 = Cl, R2 = H, R3 = Cl, R4 = CH3  
13 Fasamycin F R1 = H, R2 = COOH, R3 = H, R4 = H 
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2 Formicapyridine B R1 = CH3, R2 = H, R3 = H  
3 Formicapyridine C R1 = CH3, R2 = CH3, R3 = H  
4 Formicapyridine D R1 = H, R2 = H, R3 = Cl
5 Formicapyridine E R1 = CH3, R2 = H, R3 = Cl
6 Formicapyridine F R1 = CH3, R2 = CH3, R3 = Cl   
7 Formicapyridine G R1 = H, R2 = H, R3 = Br  
8 Formicapyridine H R1 = CH3, R2 = H, R3 = Br   
9 Formicapyridine I R1 = CH3, R2 = CH3, R3 = Br   
1
6
4
9 14
18
22
R2
Fig. 1 Chemical structures of metabolites isolated from Streptomyces formicae. Compounds 1–9 and 13 were discovered during this study whereas 10–12 and
14–26 were reported in an earlier study5
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11538-6 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3611 | https://doi.org/10.1038/s41467-019-11538-6 | www.nature.com/naturecommunications 3
fasamycins5. However, despite scaling up production to isolate
additional 2, meaningful ECD spectra could not be obtained. Full
characterization data for 1–6 are presented in Supplementary
Note 1. Due to the very low levels of 7–9, we have assigned
preliminary structures based on 4–6, with a bromine atom
replacing chlorine at C14.
Compounds 1–6 displayed no antibacterial activity against
Bacillus subtilis 16812 using overlay assays at 5 µg mL−1 (the
average concentration for illustrating fasamycin and formicamy-
cin bioactivity). Similarly, no inhibition was seen at tenfold this
concentration (50 µg mL−1), with only small zones of inhibition
at 100-fold (500 µg mL−1). To confirm this was not a result of
reduced diffusion from the disc, assays were set up to test growth
of B. subtillis 168 in liquid cultures containing compounds 1–6,
but again they showed no activity.
Biosynthetic origins. Interrogation of LC-HRMS data from
extracts of the Δfor and ΔforV mutants verified that the fasa-
mycin/formicamycin BGC is required for formicapyridine pro-
duction. The Δfor mutant does not produce 1–6 (Supplementary
Fig. 3b vs. 3a), but production of all six compounds was restored
upon ectopic expression of the P1-derived artificial chromosome
(PAC) pESAC13–215-G containing the entire formicamycin BGC
(Supplementary Fig. 3c). Similarly, the ΔforV mutant does not
produce 4–6 (Supplementary Fig. 3d), but their production is re-
established upon ectopic expression of forV under the control of
the native promoter using an integrative plasmid (Supplementary
Fig. 3e) (the construction of all strains, the requirement of the for
BGC for production of the fasamycins and formicamycins, and
the requirement of ForV for their halogenation were described
previously5).
The very low level of formicapyridines made by the WT strain
suggests they are shunt metabolites arising from aberrant
derailment of fasamycin/formicamycin biosynthesis. On this
basis, we suggest a biosynthetic pathway as described in Fig. 4.
Assembly of the poly-β-ketone tridecaketide intermediate should
proceed as previously proposed on route to the fasamycins5. This
would be followed by a series of cyclization and aromatisation
steps, presumably in a sequential manner, with the final
cyclization event probably involving formation of the B-ring.
However, premature hydrolysis of the acylcarrier protein from
putative intermediate 27, prior to the action of a final cyclase,
would liberate the enzyme-free, β-ketoacid species 28 that would
be highly facile to spontaneous decarboxylation yielding the
methylketone 29. The action of an endogenous aminotransferase
could then generate either of the species 30 or 31, which could
undergo cyclization, dehydration and oxidation to yield 1.
Consistent with a shunt pathway, no aminotransferase encoding
gene could be identified in the for BGC, and although numerous
putative aminotransferase encoding genes were identified in the
genome, none could be linked to a role in formicapyridine
biosynthesis. Alternatively, direct addition of ammonia to the C23
ketone would generate an imine, tautomerize to the enamine, and
the resulting amino group could then attack the C7 ketone.
Subsequent dehydration would lead directly to the formicapyr-
idine system with no requirement of an oxidation reaction.
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Fig. 2 Metabolomics pipeline. Dereplication, based on for biosynthetic mutants and exogenous bromide addition, led to the identification of the new
congeners 4–9 with characteristic halogen-containing patterns (strain ΔforV lacks a halogenase gene; Δfor lacks the entire biosynthetic gene cluster)
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This pathway requires that C25 of the formicapyridines
originates from C2 of an acetate unit, with C1 lost via
decarboxylation. To support our hypothesis, and the backbone
structural assignments, S. formicae KY5 was cultivated on MS
agar plates for two days and then overlaid with a solution of
[1,2-13C2] sodium acetate (1 mL of 60 mM solution; final
concentration 2 mM). This was repeated on the four following
days, and after a total of 9 days incubation the agar was extracted
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Fig. 3 Structure determination. The COSY (black bold), NOESY (red double headed arrows) and HMBC (blue single headed arrows) correlations for
formicapyridine B (2), along with the two resulting substructures are shown (Sub 1 and Sub 2)
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Fig. 4 Proposed biosynthesis of the formicapyridine backbone. Derailment of fasamycin biosynthesis due to premature hydrolysis of the PKS acylcarrier
protein leads to the β-ketoacid intermediate 28 which is facile to decarboxylation yielding methylketone 29. Transamination of 29 leads of amine
intermediates which can undergo spontaneous cyclization and aromatization to yield formicapyridines
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with ethyl acetate and the most abundant congener was isolated
(2, ~1 mg), and the 13C NMR spectrum was acquired. Due to the
small amount of material, and overlapping signals, only eight of
the intact acetate units could be unambiguously identified based
on their coupling contests. In addition, a singlet was observed for
C25 which showed weak enrichment (Fig. 5; Supplementary
Fig. 4). This is consistent with our biosynthetic hypothesis, which
requires that the carbon atom at C25 derives from C2 of a
fragmented acetate unit. The data were in accordance with the
proposed structure for 2.
Targeted evolution of the for BGC. Our biosynthetic proposal
led to the following thought experiment. Suppose, in some
environmental scenario, the presence of formicapyridines leads to
a selection advantage. Is there then a single mutation in the BGC
that could rapidly lead to enhanced levels of their production,
and, in addition, could such changes lead to the reduction or even
abolition of fasamycin/formicamycin biosynthesis?
The proposed biosynthetic pathway likely requires the action of
multiple polyketide cyclase/aromatase enzymes and this suggests
that one cyclase could be dedicated to formation of ring-B in the
final step of backbone biosynthesis (Fig. 4). On this basis we
hypothesised that mutation of a gene encoding a putative ring-B
cyclase might lead to the phenotype imagined in our thought
experiment by eliminating the biosynthesis of fasamycins/
formicamycins and shunting carbon flux into the proposed
formicapyridine pathway. BLAST and conserved domain analysis,
in conjunction with structural modelling using the Phyre2 web
portal for protein modelling and analysis13, allowed us to identify
five genes in the for BGC, which might encode potential cyclase/
aromatase enzymes (Table 1).
The gene product ForD shows significant sequence similarity
to aromatase/cyclases such as the N-terminal domain (pfam
03364) of the archetypical tetracenomycin polyketide cyclase
TcmN, which belongs to the Bet v1-like superfamily (cl10022)14.
In vivo analysis15–17 and in vitro reconstruction18 showed that
TcmN catalyses formation of the first two rings of tetracenomycin
via sequential C9–C14 and C7–C16 cyclization/aromatization
reactions. Thus, we predict ForD, which will play a key role in
formation of the rings E and D during fasamycin biosynthesis.
The ForL gene product belongs to the TcmI family of polyketide
cyclases (cl24023; pfam 04673). The function of TcmI has been
verified by in vivo mutational analysis19 and biochemical
characterisation20,21. It catalyses cyclization of the final ring
during formation of tetracenomycin F1 from tetracenomycin F2,
and this reaction is remarkably like that proposed in our
hypothesis for the formation of ring-B as the final step of
fasamycin backbone assembly (Fig. 4). ForR is a homologue of the
zinc containing polyketide cyclase RemF from the resistomycin
BGC22,23. RemF is a single domain protein (pfam 07883)
comprising the conserved barrel domain of the cupin superfamily
(cl21464)24. Finally, the gene products ForS and ForU are both
single domain proteins (pfam 03992) belonging to the ABM
superfamily (cl10022). A notable member of this family is
ActVA-orf6, which functions as a monooxygenase during
biosynthesis of the polyketide antibiotic actinorhodin; the
structure of this enzyme has been solved and it is topologically
related to the PKS cyclase TcmI and homologues25. Notably,
ABM family domains are found in several PKS cyclases including
the C-terminal domain of BenH from the benastatin BGC26,27,
which also comprises an N-terminal TcmN like cyclase domain
(pfam 03364); and WhiE Protein 1 and other members of the
SchA/CurD-like family of PKS enzymes commonly associated
with BGCs for the biosynthesis of spore pigments in Streptomyces
spp28–30. SchA/CurD- and WhiE Protein 1-like enzymes are
comprised of an N-terminal ABM domain and a C-terminal PKS
cyclase domain (pfam 00486; superfamily cl24023).
To interrogate their roles, we used Cas9-mediated genome
editing31 to make in-frame deletions in each of these five putative
cyclase genes (forD, forL, forR, forS and forU). Three independent
C24
C25C1
27 26 25 24 23 22 21 20
f1 (ppm)f1 (ppm)
138.9 138.2 13 19 18 17 1516
J = 44.58 HzJ = 44.58 Hz
//
25
24
1
Fig. 5 The methyl group carbon C25 arises from C2 of acetate. Comparison of 13C NMR spectra for 2 isolated after growth in the presence of [1,2-13C2]
sodium acetate. Integration of the 13C NMR spectra confirmed weak enrichment of the 13C isotope and the absence of coupling to any adjacent carbon
atom. In contrast, the methyl group atom C24 shows enrichment and coupling to C1. The C2 atom of [1,2-13C2] sodium acetate is highlighted as a blue
circle, the C1 atom as a black circle, and the coupled unit by a bold line
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mutants generated from each gene deletion experiment, along
with the WT strain, were grown on MS agar and cultured at 30 °C
for 9 days. To assess differences in secondary metabolite
production the ethyl acetate extracts from each culture were
subjected to HPLC(UV) and LCMS analysis (Supplementary
Data 3 and 4). The metabolic profiles showed that the ΔforD,
ΔforL, ΔforR and ΔforU mutants lost the ability to produce
formicapyridines, fasamycins and formicamycins (Supplementary
Figs. 5–9), and no new shunt metabolites could be identified
despite rigorous interrogation of the LCMS and LC(UV) data.
These deletions could be rescued by complementation with the
deleted gene under control of either the native promoter (ΔforD/
forD and ΔforL/forL) or the constitutive ermE* promoter (ΔforR/
forR), although the titres did not reach that of the WT strain in all
cases. For the ΔforU mutant complementation with forU restored
production of the non-halogenated congener 10 only, indicating a
polar effect on the downstream halogenase forV gene. Subsequent
complementation with a forUV cassette under the ermE*
promoter in which the two genes were transcriptionally fused
led to the production of halogenated fasamycin and formicamy-
cin congeners.
In contrast, production of formicapyridines was increased ∼25-
fold in the ΔforS mutant when compared with the WT (Fig. 6).
These effects were complemented by ectopic expression of forS
under the control of the ermE* promoter. Moreover, the ΔforS
mutant was significantly compromised in its ability to produce
formicamycins, with their titre being reduced to approximately
one third that of the WT strain. This is consistent with our
hypothesis for formicapyridine biosynthesis and suggests that
ForS plays a role during B-ring closure, and that this constitutes
the final step of fasamycin backbone biosynthesis. It also
demonstrates that the final cyclization step can still occur without
ForS. While carrying out analysis of the ΔforS mutant we
identified a minor congener, which was not identified in any WT
strain fermentations. Scale up growth (4 L) and solvent extrac-
tion, followed by isolation (3.4 mg) and structural elucidation
identified this compound (13) as the C24-carboxyl analogue of
fasamycin C (which we have named fasamycin F). This is the first
congener identified with the C24-carboxyl group intact.
Discussion
Using targeted metabolomics, we identified a family of pyridine
containing polyketide natural products that we have named the
formicapyridines. Remarkably, these compounds are derived
from the fasamycin/formicamycin biosynthetic machinery
meaning that the for BGC is responsible for the production of
three structurally differentiated pentacyclic scaffolds. Inspired by
evolutionary considerations we introduced a gene deletion into
the BGC, which significantly altered the relative levels of these
metabolites: the titre of formicapyridines was significantly
increased (∼25-fold) in contrast to the fasamycin/formicamycins,
which were decreased to approximately one-third of the WT titre.
These results raise a series of questions about the cyclization
events associated with the fasamycin/formicamycin biosynthetic
pathway, and with the maintenance of pathway fidelity.
Our data suggest that formation of ring-B of the fasamycin
scaffold is the final biosynthetic step, followed by thioester
hydrolysis to liberate the ACP and subsequent decarboxylation to
remove the carboxyl group attached to C24 (Fig. 5). Consistent
with this, deletion of forS led to the isolation of shunt metabolite
13 with a C24-carboxyl group that was not observed from the
WT. However, while ForS is implicated in ring-B cyclization it is
not required for this role, nor, apparently, for the biosynthesis of
any congeners. Rather, ForS seems to decrease the production of
aberrant congeners from the pathway, e.g. formicapyridines,
while increasing overall productivity. The most parsimonious
interpretation of these data is that another of the for BGC gene
products is the actual catalyst for ring-B formation, and that ForS
acts as a chaperone, which modulates or stabilises the assembly,
or arrangement, of a multienzyme complex to optimise produc-
tion of the fasamycins, and therefore ultimately the for-
micamycins. This has the consequence of minimising the
production of shunt metabolites (formicapyridines). Thus, while
deletion of forS leads to the phenotype desired from our thought
experiment, the mechanism by which this occurs is not what was
anticipated. Interpretation of the for BGC bioinformatic analysis
suggests the most likely candidate for a ring-B (final) cyclase is
ForL due to its close relationship with TcmI, which catalyses a
similar final cyclization step during tetracenomycin biosynth-
esis19–21. The apparent lack of any intermediates or shunt
metabolites being accumulated by the remaining mutants is
somewhat surprising and suggests an absolute requirement for
the formation of a PKS-cyclase complex before biosynthesis can
be initiated.
These observations are reminiscent of studies regarding the
biosynthesis of pradimicin32. Pradimicins are pentangular poly-
ketides similar to the benastatins26,27, and the BGC for their
production contains three PKS cyclases equivalent to ForD
(PdmD), ForL (PdmK) and ForR (PdmL)32,33. It also contains
two ABM domain proteins (PdmH and PdmI; c.f. ForS and ForU)
which were assigned monooxygenase roles. Through hetero-
logous expression of PKS gene cassettes it was deduced that for
the biosynthetic pathway to function correctly, and yield a pen-
tangular backbone, all three cyclase genes (PdmDKL) plus the
ABM domain monooxygenase PdmH must be co-expressed. In
this pathway one oxidation reaction to form the quinone struc-
ture is required. These results led the authors to propose a model
in which the two cyclases PdmKL and the monooxygenase PdmH
form a multienzyme complex that engulfs the entire polyketide
molecule during its assembly and work synergistically to ensure
the correct reaction pathway occurs thereby minimising
the production of shunt metabolites32. Similarly, formation of the
unusual discoid metabolite resistomycin involves an extremely
rare S-shaped folding pattern and requires the coordinated
function, likely as a multienzyme complex, of core PKS proteins
in addition to three distinct cyclase enzymes23. Moreover, het-
erologous reconstruction of the resistomycin pathway gave no
products when the minimal PKS plus first cyclase were assem-
bled23, a rare observation that is in keeping with our data showing
the requirement of all the putative cyclases ForDLRU to produce
any pathway derived metabolites, including shunts.
Table 1 Characteristics of the putative PKS cyclase genes in the for BGC
Name Sequence identity Top BLASTp hit Annotation % Coverage % Identity
ForD WP_098245758.1 WP_003962252.1 Polyketide cyclase (TcmN), Streptomyces clavuligerus ATCC 27064 95 73
ForL WP_055544278.1 WP_076971949.1 TcmI family type II polyketide cyclase, Streptomyces sparsogenes 97 52
ForR WP_098245762.1 AUI41024.1 Polyketide WhiE II Streptomyces sp., cupin domain 96 75
ForS WP_098245763 SDF47214.1 Antibiotic biosynthesis monooxygenase, Lechevalieria fradiae 96 48
ForU WP_098245765.1 PZS28546.1 Antibiotic biosynthesis monooxygenase, Pseudonocardiales bacteria 84 46
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Biosynthesis of the for BGC polyketide backbones does not
require a monooxygenase. Consistent with this, deletion of forS
does not abolish polyketide production, but instead affects
pathway productivity and fidelity. Thus, based on our mutational
data and the observations discussed above, we hypothesise that
ABM family enzymes can act as monooxygenases and/or as
ancillary proteins to tune, in some way, the PKS enzyme complex
function, and therefore the biosynthetic pathway, during aromatic
polyketide biosynthesis. Genes encoding these proteins occur
commonly in PKS BGCs, and multiple paralogues are often
present even when monooxygenase reactions are not required. It
is noteworthy that several PKS cyclases occur as fusion proteins
with an ABM domain, which can be located at either terminus.
We speculate that these may represent examples of mature
pathways where the chaperone-like function of the ABM family
protein has become essential, leading to selective pressure for the
encoding gene to become transcriptionally fused with other
cyclase encoding genes.
Methods
Chemistry methods and materials. Unless stated otherwise all chemicals were
supplied by Sigma-Aldrich or Fisher Scientific. [1,2-13C2] sodium acetate was
purchased from CORTECNET. All solvents were of HPLC grade or equivalent.
NMR spectra were recorded on a Bruker Avance III 400MHz NMR spectrometer
equipped with 5 mm BBFO Plus probe. 13C NMR spectra for 2 and isotopically
enriched 2 after feeding [1,2-13C2] sodium acetate were recorded on a Bruker
Avance III 500MHz NMR spectrometer equipped with a DUL cryoprobe at 30 °C.
Unless otherwise stated samples were analysed by LCMS/MS on a Nexera/
Prominence UHPLC system attached to a Shimadzu ion-trap time-of-flight
mass spectrometer. The spray chamber conditions were: heat block, 300 °C; 250°
curved desorbtion line; interface (probe) voltage: 4.5 KV nebulizer gas flow rate
1.5 L min−1; drying gas on. The instrument was calibrated using sodium
trifluoroacetate cluster ions according to the manufacturer’s instructions and run
with positive–negative mode switching. The following analytical LCMS method
was used throughout this study unless otherwise stated: Phenomenex Kinetex C18
column (100 × 2.1 mm, 100 Å); mobile phase A: water +0.1% formic acid; mobile
phase B: methanol. Elution gradient: 0–1 min, 20% B; 1–12 min, 20–100% B;
12–14 min, 100% B; 14–14.1 min, 100–20% B; 14.1–17 min, 20% B; flow rate
0.6 mLmin−1; injection volume 10 µL. Samples were prepared for LCMS analysis
by taking a rectangle of agar (2 cm3) from an agar plate culture and shaking with
ethyl acetate (1 mL) for 20 min. The ethyl acetate was transferred to a clean tube
and the solvent removed under reduced pressure. The resulting extract was
dissolved in methanol (200 µL).
Standard microbiology and molecular biology methods. All strains used or
made in this study are described in Supplementary Table 1. All plasmids and
ePACs used are described in Supplementary Table 2. All PCR primers used are
described in Supplementary Data 5. The compositions of media used are described
in Supplementary Table 3. The antibiotics and their concentrations used are
described in Supplementary Table 4. Standard DNA sequencing was carried out by
Eurofins Genomics using the Mi×2Seq kit (Ebersberg, Germany).
E. coli strains were cultivated at 37 °C in LB Lennox Broth (LB), shaking at
220 rpm, or LB agar supplemented with antibiotics as appropriate. S. formicae was
cultivated at 30 °C on MS agar or MYM agar with appropriate antibiotic selection.
To prepare Streptomyces spores, material from a single colony was plated out using
a sterile cotton bud and incubated at 30 °C for 7–10 days until a confluent lawn had
grown over the entire surface of the agar. Spores were harvested by applying 20%
glycerol (2 mL) to the surface of the agar plate culture and gently removing spores
with a sterile cotton bud before storing them at −80 °C. Glycerol stocks of E. coli
were made by pelleting the cells from an overnight E. coli culture (3–5 mL) in a
bench top centrifuge (2773 × g, 5 min) and resuspending in fresh, sterile 1:1 2YT/
40% glycerol (1 mL). Glycerol stocks were stored at −80 °C.
S. formicae genomic DNA and cosmid ePAC DNA (from E. coli DH10B) was
isolated using a phenol:chloroform extraction method. Briefly, cells from an
overnight culture (1 mL) were pelleted at 30,000 x g in a benchtop microcentrifuge
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and resuspended in solution 1 (100 µL) (50 mM Tris/HCl, pH 8; 10 mM EDTA).
Alkaline lysis was performed by adding solution 2 (200 µL) (200 mM NaOH; 1%
SDS) and mixing by inverting. Solution 3 (150 µL) (3 M potassium acetate, pH 5.5)
was added and samples mixed by inverting, before the soluble material was
harvested by microcentrifugation at 30,000 × g for 5 min. The nucleic acid was
extracted with 25:24:1 phenol:chloroform:isoamyl alcohol (400 µL), and DNA was
precipitated in 600 µL ice-cold isopropanol. After centrifugation, the resulting
DNA pellet was washed in 200 µL 70% ethanol and air dried before being
resuspended in water for quantification on a Nanodrop 2000c UV–Vis
spectrophotometer. Plasmid DNA was isolated from E. coli strains using a Qiagen
miniprep kit according to the manufacturer’s instructions. PAC pESAC13–215-G
DNA, containing the entire for BGC, was used as the template for all PCR
reactions. DNA amplification for cloning was conducted using Q5 Polymerase and
diagnostic PCR was set up using PCRBIO Taw Mix Red (PCR Biosystems), as per
the manufacturers’ instructions. Amplified fragments and digested DNA products
were purified on 1% agarose gels by electrophoresis and extraction using the
Qiagen gel extraction kit as per the manufacturer’s instructions. For overlay
bioassays soft LB agar (100 mL LB with 0.5% agar) was inoculated with Bacillus
subtillis 168 (10 mL; approximately OD600= 0.6). Set concentrations of the
compound for testing were made up in methanol and an aliquot (20 µL) was
applied to Whatman 6mm antibiotic assay discs, air dried, and the discs placed in
the centre of the solidified agar plates. Plates were incubated at 30 °C overnight
before being examined for zones of inhibition around the discs. For liquid culture
bioassays, cultures of B. subtillis 168 (1 mL) were grown at 30 °C, 200 rpm shaking,
with the relevant antibiotic (50 µg mL−1). After 7 h incubation, samples were taken
from the cultures, diluted in series and plates for colony count in triplicate
following Miles and Misra protocol34.
Generating mutant strains of S. formicae. CRISPR/Cas9 genome editing was
conducted using the pCRISPomyces-2 plasmid supplied by Addgene. Protospacers
to use in the synthetic guide RNA (sgRNA) were annealed by heating to 95 °C for
5 min followed by ramping to 4 °C at 0.1 °C s−1. Annealed protospacers were
assembled into the pCRISPomyces-2 backbone at the BbsI site by Golden Gate
assembly. The two homology repair template arms (each ∼1 kb) were PCR-
amplified as above and assembled into the plasmid containing the sgRNA at the
XbaI site using Gibson Assembly5,31. Genetic complementation was achieved using
either the native promoter or the constitutive, high-level ermE* promoter and
single copies of the relevant gene(s) cloned into the integrative vector pMS82 or
pIJ10257, respectively. Gibson assembly was used to fuse the gene(s) (and the
native promoter if located distally in the BGC) and assemble them into the chosen
plasmid. Plasmids were confirmed by PCR amplification and sequencing. Plasmids
were then conjugated into S. formicae KY5 via the non-methylating E. coli strain
ET12567 containing pUZ800235. Ex-conjugants were selected on the appropriate
antibiotics and pCRISPomyces-2 plasmids were cured from S. formicae using
temperature selection at 37 °C.
Isolation and structure determination of formicapyridines. S. formicae was
cultivated on MS agar (14 L, ∼450 plates) at 30 °C for 9 days. The agar was sliced
into small pieces and extracted twice with ethyl acetate (10 L) using ultrasonication
to improve the extraction. The extracts were combined, and the solvent removed
under reduced pressure to yield a brown oil, which was dissolved in methanol
(20 mL). This extract was first chromatographed over a Phenomenex Gemini-NX
reversed-phase column (C18, 110 Å, 150 × 21.2 mm) using a Thermo Scientific
Dionex Ultimate 3000 HPLC system and eluting with the following gradient
method: (mobile phase A: water +0.1% formic acid; mobile phase B: acetonitrile)
0–5 min 40% B; 5–35 min 40–100% B; 35–40 min 100% B; 40–40.1 min 100–40%
B; and 40.1–45 min 40% B; flowrate 20 mLmin−1; injection volume 1mL.
Absorbance was monitored at 250 nm. Fractions (20 mL) were collected and
analysed by LCMS. Fractions 2–4 contained 1–6 and were further purified by
chromatography over a Phenomenex Gemini-NX semi-prep reversed-phase col-
umn (C18, 110 Å, 150 × 10 mm) using an Agilent 1100 series HPLC system and
eluting with the following gradient method: (mobile phase A: water +0.1% formic
acid; mobile phase B: acetonitrile) 0–2min 40% B; 2–20min 40–100% B; 20–21min
100% B; 21–21.1 min 100–40% B; 21.1–23min 40% B; flowrate 3 mLmin−1;
injection volume 100 µL). Absorbance was monitored at 390 nm. The samples were
finally purified by Sephadex LH20 size exclusion chromatography with 100%
methanol as the mobile phase. The isolated yields were: 1 (1 mg), 2 (2 mg), 3
(2 mg), 4 (0.7 mg), 5 (1 mg) and 6 (0.6 mg). These pure compounds were subjected
to analysis by HRMS and 1D and 2D NMR as described in the main text (see
Figs. 1 and 2). Spectroscopic and other data for each compound is presented
in Supplementary Information (Supplementary Figs. 15–38 and Supplementary
Note 1).
Stable isotope feeding experiment. S. formicae was cultivated on MS agar (3 L;
∼100 plates) at 30 °C and overlaid with [1,2-13C2] sodium acetate (1 mL of a
60 mM solution) after 24 h, 48 h, 72 h, 96 h and 120 h. After a further 72 h the agar
was extracted and purified using the methods described above to yield a sample of
2 (0.9 mg). This material was analyzed by LCMS and inverse gated 13C NMR
(125MHz; 4096 scans; d4-methanol). However, due to the weak and overlapping
signals, only the following coupling constants (JCC) of the intact acetate units were
recorded: C24–C1, 44.61 Hz; C2–C3, 68.58 Hz; C4–C5, 68.16 Hz; C20–C21,
56.18 Hz. In addition, C14, C16, C18 and C22 have coupling constants of 66.47,
67.61, 42.08 and 60.43 Hz, respectively. Spectroscopic data is presented in Fig. 5
and Supplementary Fig. 4.
Isolation and structure determination of fasamycin F (13). S. formicae ΔforS
was cultivated on 4 L (~120 plates) of MS agar at 30 °C for nine days. The agar was
extracted and purified using the methods described above to yield 13 (3.4 mg). This
material was analysed by LCMS and 1D and 2D NMR (100MHz; 6500 scans; d4-
methanol). Spectroscopic data is presented in Supplementary Figs. 39–43.
Congener content analysis of cyclase mutants. S. formicae WT or mutant
strains (n= 3) were grown on MS agar at 30 °C for nine days. A rectangle of agar
(2 cm3) was excised from each petri dish, sliced into small pieces and shaken
with ethyl acetate (1 mL) for 20 min. The ethyl acetate was transferred to a clean
tube and the solvent removed under reduced pressure. The resulting extract was
dissolved in methanol (200 µL) and analysed by LCMS but using the following
modified UPLC method: Phenomenex Gemini C18 column (100 × 2.1 mm,
100 Å); mobile phase A: water +0.1% formic acid; mobile phase B: methanol.
Elution gradient: 0–2 min, 50% B; 2–14 min, 50–100% B; 14–18 min, 100% B;
18–18.1 min, 100–50% B; 18.1–20 min, 50% B; flow rate 1 mL min−1; injection
volume 10 μL.
Calibration curves (Supplementary Fig. 10; Supplementary Data 3) were
determined using standard solutions of fasamycin C 10 (10, 20, 50, 80 and
200 µM), formicamycin C 16 (10, 20, 50, 100 and 200 µM), formicapyridine D 4 (5,
10, 25, 50 and 100 µM) and fasamycin F 13 (5, 20, 40, 80 and 150 µM). The content
of 10 and 16 was determined by UV absorption at 285 nm. The content of 4 and 13
was determined by MS analysis of the base peak chromatogram (positive mode).
Each standard solution was measured three times.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this work are available within the paper and
its Supplementary Information files. A reporting summary for this Article is available as
a Supplementary Information file. The datasets generated and analyzed during the
current study are available from the corresponding author upon request. The source data
underlying Fig. 6e–h are provided as a Source Data file.
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